Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 4/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19160427 | 0.78 | GCK (0.42) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL19160470 | 0.77 | KMT2A (0.38) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL19160413 | 0.77 | KMT2A (0.38) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL19160609 | 0.75 | KMT2A (0.40) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL19160376 | 0.74 | AXL (0.41) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL19160450 | 0.72 | HPGD (0.39) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL19160471 | 0.72 | KMT2A (0.44) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL2395594 | 0.72 | IRAK4 (0.38) | KDM4EHPGDHSD17B10TDP1ALDH1A1 | |
| SCHEMBL19160416 | 0.71 | KMT2A (0.38) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL9900202 | 0.71 | KMT2A (0.40) | KMT2AKDM4EMEN1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230558-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-01-25 | — | — | US | disclosed |
| US-11008341-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-05-18 | — | — | US | disclosed |
| US-10865214-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | The Trustees of Columbia University in they City of New York (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200216469-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | UNIV COLUMBIA (US) | 2020-07-09 | — | — | US | disclosed |
| US-10626124-B2 | — | — | 2020-04-21 | — | — | US | disclosed |
| US-20190112317-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | NY STATE PSYCHIATRIC INSTITUTE | 2019-04-18 | — | — | US | disclosed |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2017-07-27 | — | — | US | disclosed |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112317-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | KMT2A 4313/4885KDM4E 3589/4885MEN1 4557/4885 |
| US-11008341-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | KMT2A 4313/4885KDM4E 3589/4885MEN1 4557/4885 |
| US-10626124-B2 | — | MAPT, SQSTM1, TFEB | KMT2A 3887/4885KDM4E 3143/4885MEN1 4641/4885 |
| US-11230558-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | KMT2A 4313/4885KDM4E 3589/4885MEN1 4557/4885 |
| US-10865214-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | KMT2A 4313/4885KDM4E 3589/4885MEN1 4557/4885 |
| US-20200216469-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | KMT2A 4313/4885KDM4E 3589/4885MEN1 4557/4885 |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | KMT2A 4313/4885KDM4E 3589/4885MEN1 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.